$REGN Company News Regeneron skids on shortfall in

New Post Public Reply Private Reply Replies (0) Message Board

Nov 15, 2014 at 4:05 AM

$REGN Company News

Regeneron skids on shortfall in Eylea sales 11:15 a.m. Nov. 4, 2014 - Russ Britt
Regeneron Pharmaceuticals shares rise 8% 8:31 a.m. Oct. 17, 2014 - Sue Chang
10 rock-solid stocks for conservative investors 8:51 a.m. Sept. 17, 2014 - Philip van Doorn
S&P 500 nails the breakout point 9:35 a.m. Sept. 8, 2014 - Michael Ashbaugh
Regeneron shares run up 4.8% to lead S&P 500 gainers 8:34 a.m. Sept. 2, 2014 - Tomi Kilgore
Small health companies see large gains on a big earnings day 4:34 p.m. July 30, 2014 - Russ Britt
Twitter, U.S. Steel soar; Buffalo Wild Wings are burned 3:26 p.m. July 30, 2014 - Sue Chang
Edwards, Hospira rise as health-care companies see strong earnings 12:08 p.m. July 30, 2014 - Russ Britt
Regeneron shares jump after cholesterol drug meets test goals 10:16 a.m. July 30, 2014 - Russ Britt
Regeneron Pharmaceuticals jumps 7.7% 8:32 a.m. July 30, 2014 - Sue Chang
Dow ends at record high close but still shy of 17,000: Stock market live blog recap 3:04 p.m. July 1, 2014 - blogs.marketwatch.com
Twitter gains on new CFO; GM sales up in June 1:29 p.m. July 1, 2014 - Sue Chang
Oracle slides on disappointing results; CarMax soars 3:17 p.m. June 20, 2014 - Sue Chang
Maybe Amazon will unveil a toaster today 7:08 a.m. June 18, 2014 - Marek Fuchs
Twitter rallies ahead of earnings; 3D Systems retreats 2:49 p.m. April 29, 2014 - Sue Chang
Intuitive Surgical slumps; Facebook extends rally 2:41 p.m. April 9, 2014 - Sue Chang
44 stocks on takeover target radar: Morgan Stanley 11:48 a.m. March 25, 2014 - blogs.marketwatch.com
First Solar, H-P, Symantec are stocks to watch 3:16 p.m. March 21, 2014 - Sue Chang
First Solar extends winning streak; Symantec plunges 2:07 p.m. March 21, 2014 - Sue Chang
Nasdaq falls for 4th day in row; Dow, S&P slip for 2nd day: stock market live blog recap 2:51 p.m. March 11, 2014 - blogs.marketwatch.com

Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences 9:23 a.m. Nov. 14, 2014 - Seeking Alpha
Regeneron Pharmaceuticals, Inc. (REGN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Nov. 14, 2014 - Zacks.com
Meet 5 U.S. Techs, Biotechs With Strong Fundamentals 7:02 a.m. Nov. 13, 2014 - Investors Business Daily
3 Stocks Moving The Drugs Industry Upward 12:25 p.m. Nov. 12, 2014 - TheStreet.com
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog 11:00 a.m. Nov. 12, 2014 - Zacks.com
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog 8:48 a.m. Nov. 12, 2014 - Zacks.com
Cramer's Mad Money - The Hottest Stock You've Never Heard Of (11/11/14) 5:20 a.m. Nov. 12, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Pile Into Housing, Biotech and Pop Cult Names 8:59 p.m. Nov. 11, 2014 - TheStreet.com
Stock Market News for November 11, 2014 - Market News 10:10 a.m. Nov. 11, 2014 - Zacks.com
Today's Momo Momentum Stock To Watch: Regeneron Pharmaceuticals (REGN) 9:51 a.m. Nov. 11, 2014 - TheStreet.com
Sanofi/Regeneron asthma drug successful in Phase 2 trial 7:44 a.m. Nov. 11, 2014 - Seeking Alpha
3 Stocks Reiterated As A Buy: VZ, MRK, REGN 10:59 a.m. Nov. 10, 2014 - TheStreet.com
Regeneron updates guidance after Q3 results 11:09 a.m. Nov. 6, 2014 - Seeking Alpha
Regeneron Plunges In What Barron's Calls A Significant Disappointment: My Analysis 8:32 a.m. Nov. 6, 2014 - Seeking Alpha
20 Stocks That Could Beat the Market in November: Priceline, U.S. Steel Lead Way 11:24 a.m. Nov. 5, 2014 - TheStreet.com
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog 9:46 a.m. Nov. 5, 2014 - Zacks.com
Jazz Beats And Raises Views; Regeneron Misses In Q3 6:02 p.m. Nov. 4, 2014 - Investors Business Daily
Regeneron Q3 Earnings Up Y/Y, Narrows Eylea Guidance - Analyst Blog 4:30 p.m. Nov. 4, 2014 - Zacks.com
Regeneron Pharmaceuticals (REGN) Earnings Report: Q3 2014 Conference Call Transcript 4:16 p.m. Nov. 4, 2014 - TheStreet.com
Regeneron Q3 Earnings Miss As U.S. Eylea Sales Falter 9:51 a.m. Nov. 4, 2014 - Investors Business Daily

Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma 1:00 a.m. Nov. 11, 2014 - PR Newswire - PRF
Regeneron Reports Third Quarter 2014 Financial and Operating Results 6:30 a.m. Nov. 4, 2014 - PR Newswire - PRF
Regeneron Announces Upcoming 2014 Investor Conference Presentations 4:01 p.m. Nov. 3, 2014 - PR Newswire - PRF
Upcoming Earnings, Financial Results, New Affiliations, and Study Results - Research Reports on Regeneron, Valeant, CVS Health, CIGNA and Baxter 9:15 a.m. Nov. 3, 2014 - PR Newswire - PRF
New Solution for Patients, Quarterly Financial Results, Clinical Study Initiation, Merger Updates, and Product Launch - Research Reports on CVS, Valeant, Regeneron, Allergan and Agilent 9:20 a.m. Oct. 23, 2014 - PR Newswire - PRF
Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma 9:00 a.m. Oct. 20, 2014 - PR Newswire - PRF
Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis 7:00 a.m. Oct. 20, 2014 - PR Newswire - PRF
EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study 7:00 a.m. Oct. 17, 2014 - PR Newswire - PRF
Regeneron Ranked Number One Biopharmaceutical Employer by Science Magazine for Third Consecutive Year 2:00 p.m. Oct. 16, 2014 - PR Newswire - PRF
Regeneron Genetics Center Fully Operational, Announces New Collaborations and Key Appointments 8:30 a.m. Oct. 16, 2014 - PR Newswire - PRF
Regeneron to Report Third Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2014 4:01 p.m. Oct. 15, 2014 - PR Newswire - PRF
Critical Alerts For ITT Education, EOG Resources, Mobileye NV, CBS and Regeneron Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Oct. 10, 2014 - PR Newswire - PRF
Positive Study Results, Dividend, Regulatory Warning, Board Statements, and Technical Updates - Research Reports on Regeneron, CVS Health, Valeant, Allergan and Jazz 9:15 a.m. Oct. 7, 2014 - PR Newswire - PRF
EYLEA® (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO) 4:58 p.m. Oct. 6, 2014 - PR Newswire - PRF
Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 1:00 a.m. Sept. 30, 2014 - PR Newswire - PRF
Regulatory Approvals, Senior Notes Redemption, and Technical Updates - Research Reports on Tekmira, Regeneron, Valeant, Teva and United Therapeutics 9:20 a.m. Sept. 25, 2014 - PR Newswire - PRF
Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization (CNV) in Japan 2:30 a.m. Sept. 22, 2014 - PR Newswire - PRF
EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema 7:00 a.m. Sept. 16, 2014 - PR Newswire - PRF
Biotech Stocks Under Review -- Keryx Biopharma, Sangamo BioSciences, Regeneron Pharma, Sunesis Pharma, and Idera Pharma 9:10 a.m. Sept. 9, 2014 - PR Newswire - PRF
Critical Alerts For Rocket Fuel, General Motors, International Business Machines, Google and Regeneron Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Sept. 8, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mausam Bhatt Joins Cars.com as Chief Product Officer

Shifting Gears with a New Leader Sometimes the name alone isn't enough to get things rolling, but when someone who's built billion-dollar platforms from scratch joins your team, the engine's ready to roar. That's the motor firing up at Cars.com with Mausam Bhatt behind the wheel as their fresh Chief Product Officer. If you think a new set of eyes can only see what's...

Jay Group Expands to Houston with New Fulfillment Hub

Jay Group's Bold Move in the Logistics Arena In a no-holds-barred expansion, Jay Group's got themselves a brand new sprawling 250,000-square-foot fulfillment hub deep in the heart of Houston. Now, folks, this isn’t just another warehouse. We're talking a 3PL powerhouse that allows coast-to-coast delivery, hitting 90% of U.S. consumers in just a couple of days. If you're...

Bulletproof Gets Nod for AI Expertise, Eyes Future Growth

Bulletproof's Recognition: A Sign of AI Prowess Let's dive right into today's news: Bulletproof just snagged a spot on the 2026 CRN AI Innovators list. Now, this is big leagues stuff, especially since this list highlights the top dogs in the AI space across North America. We're talking about managed service providers, value-added resellers, and all those tech wizards who...

Arctic Wolf Leads in AI SOC: A 2026 Game Changer

Leading the Pack with AI-Powered Security In the world of cybersecurity, where every day feels like a battlefield, Arctic Wolf has clawed its way to the top spot in the Q4 2026 QKS SPARK Matrix™ for AI SOC Automation. This recognition doesn't just highlight their prowess in handling security operations; it underscores their relentless commitment to infusing AI...

Static Media Acquires CarScoops to Boost Auto Reach

Static Media's Latest Move in the Automotive Arena The digital media landscape keeps morphing, and Static Media just decided to crank up the gears a notch by snapping up CarScoops.com. For those with an eye on the automotive field, it's the kind of play that could shift the tides. Static Media, already a heavyweight with brands like Jalopnik and SlashGear under its belt,...

EDB Enhances Postgres with Horizontal Scaling Preview

EDB's Ambitious Move Into Seamless Data Growth Right out of Wilmington, Delaware, EnterpriseDB (EDB) is sowing the seeds for a seismic change in how enterprises juggle their data systems. With 86% of the top brass anticipating AI data systems becoming top-tier indispensable, the unveiling of EDB’s horizontal scaling for their Postgres AI Distributed is a tune you just...

A. O. Smith Reports Q3 2026: A Strategic Shift

A. O. Smith Navigates Change in Third Quarter 2026 It's been a gritty third quarter for A. O. Smith, as the company maneuvers through domestic challenges and crafts a strategic future with international tweaks. They've hammered out $941 million in sales but found themselves grappling with net earnings dipping to $126 million, or $0.93 per diluted share, a mere blip from...

Motiva's Q3 2026 Results: Strategic Moves Drive Growth

Strategic Transactions and Financial Highlights Motiva's third quarter of 2026 shows a company not just coasting but recalibrating its trajectory. Big moves had ripple effects on their financial landscape, most notably their sale of the Airport Platform, concluded for a hefty R$5.2 billion. Their portfolio's trimming isn't just a garage sale but a thought-out step...

Pozdeutinurad Phase 3 Success Impact on Sobi and Market

Pozdeutinurad's Phase 3 Triumph Ah, the life of biotech—constant ups and downs, but when you hit a homerun, it feels like the market stands still for a second. Pozdeutinurad's recent Phase 3 REDUCE-2 study results are one of those moments for Swedish Orphan Biovitrum AB, or Sobi for short. This study showed some seriously compelling data: clinically meaningful and...

Pelvic Health Initiative Aids Women in Need

Stepping Up For Better Health You don't see this kind of news getting plastered across the financial pages much—the human side of health. EliHealth Initiative's making strides in a realm many don’t even want to openly discuss: bladder leaks in women. Sounds unglamorous, maybe, but for millions, it's a daily ordeal. Slapping on pads and plotting bathroom routes? That's...